Trastuzumab and cardiac dysfunction: update on preclinical studies

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Trastuzumab is a HER2-targeted therapy improving survival in HER2-positive metastatic breast cancer.
• Cardiac toxicity, often asymptomatic decreases in left ventricular ejection fraction, is an identified side effect.
• The clinical significance and reversibility of trastuzumab-induced cardiac dysfunction require further investigation.

Purpose of the Study:

• To review the cardiac toxicity associated with Trastuzumab treatment.
• To explore the potential mechanisms of Trastuzumab-related cardiotoxicity.
• To discuss the utility of animal models in studying and potentially preventing this cardiac dysfunction.

Main Methods:

• Review of clinical data and case studies on Trastuzumab-associated cardiac events.
• Comparison of Trastuzumab cardiotoxicity mechanisms with other chemotherapy agents like anthracyclines.
• Discussion of ongoing research utilizing rodent and primate models to understand cardiac dysfunction.

Main Results:

• Trastuzumab significantly improves survival in HER2-positive metastatic breast cancer.
• Asymptomatic decreases in left ventricular ejection fraction are common but often reversible.
• The majority of patients with ejection fraction changes do not develop clinical cardiac dysfunction.
• Preliminary evidence suggests Trastuzumab cardiotoxicity mechanism differs from anthracyclines.

Conclusions:

• While Trastuzumab offers survival benefits, its cardiac toxicity necessitates careful monitoring.
• The reversible nature and low rate of clinical manifestation of ejection fraction changes suggest a manageable risk profile.
• Further research, particularly using animal models, is crucial for elucidating mechanisms and developing preventative strategies for Trastuzumab-associated cardiotoxicity.